FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION)
FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION)
May 01, 2018
Supporting Materials:
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that the Food and Drug Administration (FDA) has released Theratechnologies from post-approval commitments related to the approval of EGRIFTA®.